Recent News

• 08.07.2026 - aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
• 07.15.2026 - Evaluating Efzofitimod in a Subset of Sarcoidosis with the Restrictive Phenotype
• 07.15.2026 - aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
• 06.15.2026 - Natural Asp-tRNA Synthetase Fragment Interacts with LTBP-1 on the ECM Promoting Myofibroblast Apoptosis and Reducing Fibrosis
• 05.15.2026 - aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
• 05.13.2026 - aTyr Pharma to Participate in Upcoming Investor Conferences
• 05.11.2026 - aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
• 03.05.2026 - aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
• 02.20.2026 - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.18.2026 - aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Recent Filings

• 08.07.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.03.2026 - 8-K Current report
• 08.03.2026 - EX-99.1 EX-99.1
• 07.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.17.2026 - 4 Statement of changes in beneficial ownership of securities